# EDGAR Filing Document

**Accession Number:** 0001650664
**File Stem:** 0001650664-25-000106
**Filing Date:** 2025-6
**Character Count:** 11199
**Document Hash:** 805f57519ec2c0071bb12b984c8e2a79
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001650664-25-000106.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001650664-25-000106

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Editas Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001650664
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464097528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37687
- **FILM NUMBER:** 251041614

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-401-9000

**MAIL ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

?xml version='1.0' encoding='ASCII'? edit-20250612

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________________________________________________

**FORM 8-K**

_________________________________________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 12, 2025

_________________________________________________________________________________________

**Editas Medicine, Inc.**

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37687** | **46-4097528** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | | |
|:---|:---|:---|
| **11 Hurley Street** | **11 Hurley Street** | |
| **Cambridge,** | **Massachusetts** | **02141** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | EDIT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On June 12, 2025, Editas Medicine, Inc. (the "Company") issued a press release titled "Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables *In Vivo HBG1/2* Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June," a copy of which is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On June 12, 2025, the Company announced new *in vivo* data demonstrating therapeutically relevant levels of *HBG1/2* promoter editing in hematopoietic stem cells ("HSCs") with a single dose of proprietary targeted lipid nanoparticle ("tLNP") in non-human primates ("NHPs").

In this study, the Company's proprietary tLNP formulation delivered *HBG1/2* promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the *HBG1/2* promoter region of 58% in HSCs, exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with the Company's tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press release issued by the Company on June 12, 2025\*](a2025ehadatapressrelease-f.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\*This exhibit shall be deemed to be furnished and not filed.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | EDITAS MEDICINE, INC. | EDITAS MEDICINE, INC. |
| Date: June 12, 2025 | By: | /s/ Amy Parison |
|  |  | Amy Parison |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)

**Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables *In Vivo HBG1/2* Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June**

*Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy*

*Achievement supports development of a novel,* in vivo *approach to treating sickle cell disease and beta thalassemia.*

**CAMBRIDGE, Mass.,** June 12, 2025 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new *in vivo* data demonstrating therapeutically relevant levels of *HBG1/2* promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting *HBG1/2* promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative *in vivo* gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14<sup>th</sup> 6:30 - 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.

In this study, the Company's proprietary tLNP formulation delivered *HBG1/2* promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the *HBG1/2* promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs.

"These data from our *in vivo* HSC program confirms our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validates the further development of Editas' proprietary HSC-tLNP for editing of the *HBG1/2* promoters for the treatment of sickle cell disease and beta thalassemia," said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.

Editas Medicine's *in vivo* HSC program targets *HBG1/2* promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the *HBG1/2* promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials.

&nbsp;&nbsp;&nbsp;&nbsp;

------

The presentation details are listed below. Abstracts can be accessed on the <u>EHA website</u>, and the presentation will be posted on the <u>Editas Medicine website</u> during the conference.

**<u>Poster Presentation Details:</u>** 

**Title:** Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables *In Vivo HBG1/2* Promoter Editing for β-hemoglobinopathies

**Date/Time:** Saturday, June 14, 2025, 6:30 - 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT

**Location:** Allianz MiCo, Milano Convention Centre

**Session:** Poster Session 2

**About Editas Medicine**

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of *in vivo* medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision *in vivo* gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit <u>www.editasmedicine.com</u>.

###

**Media and Investor Contacts:**

<u>media@editasmed.com</u> 

<u>ir@editasmed.com</u>

&nbsp;&nbsp;&nbsp;&nbsp;

<br>